ABT vs EXEL: Which Stock Is the Better Buy?
Abbott Laboratories and Exelixis, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — ABT vs EXEL, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Abbott Laboratories (ABT) | Exelixis, Inc. (EXEL) | |
|---|---|---|
| Market cap | $182.9B | $13.4B |
| Revenue (latest FY) | $44.33B | $2.32B |
| Net income (latest FY) | $6.52B | $782.57M |
| Revenue growth (5y CAGR) | 5.1% | 18.6% |
| Net margin | 14.7% | 33.7% |
| Return on equity | 12.5% | 36.2% |
| P/E ratio | 34.2 | 17.6 |
| Dividend yield | 2.4% | — |
| Profitable years (of last 10) | 10 | 9 |
| Positive free cash flow | Yes | Yes |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full ABT vs EXEL breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open ABT's full financials → Open EXEL's full financials →More comparisons
Frequently asked questions
Which is bigger, ABT or EXEL?
Abbott Laboratories is larger by market capitalization — $182.9B versus $13.4B.
Which grows faster, ABT or EXEL?
Over the last five fiscal years, Exelixis, Inc. grew revenue faster — 18.6%/yr versus 5.1%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.